<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03134118</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1525</org_study_id>
    <secondary_id>2015-005504-28</secondary_id>
    <secondary_id>ETOP 11-16</secondary_id>
    <nct_id>NCT03134118</nct_id>
  </id_info>
  <brief_title>Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)</brief_title>
  <acronym>NIVOTHYM</acronym>
  <official_title>Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Thoracic Oncology Platform</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the phase II Nivothym study is to collect data on activity and toxicity of&#xD;
      nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously&#xD;
      received a first platinum-based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Rate (PFSR) at month 6</measure>
    <time_frame>The Progression Free Survival Rate (PFSR) analysis will be performed at month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>32 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>32 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according CTCAE version 4.03</measure>
    <time_frame>32 months after first patient in</time_frame>
    <description>This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, for adverse event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>32 months after first patient in</time_frame>
    <description>Overall Response Rate (ORR) will be measured according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>32 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>32 months after first patient in</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Thymoma Type B3</condition>
  <condition>Thymic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <other_name>BMS-936558-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Relapsed/advanced thymoma B3 and thymic carcinoma not amenable to curative-intent radical&#xD;
        treatment;&#xD;
&#xD;
        At least one previous line of platinum-based chemotherapy for advanced disease&#xD;
&#xD;
          -  Patients treated with neo-adjuvant or adjuvant platinum based chemotherapy combined&#xD;
             with radical surgical or as part of radical chemoradiotherapy are eligible if&#xD;
             chemotherapy was completed less than 6 months before enrollment;&#xD;
&#xD;
          -  Radiological progression documented per RECIST 1.1 during or after completion of&#xD;
             previous line therapy;&#xD;
&#xD;
          -  Presence of measurable disease according to RECIST 1.1.&#xD;
&#xD;
          -  Disease status must be documented by full chest and upper abdomen (including adrenal&#xD;
             glands) CT and/or MRI within 28 days of study enrollment. If clinically indicated,&#xD;
             brain imaging must be performed&#xD;
&#xD;
          -  At least 18 years;&#xD;
&#xD;
          -  WHO Performance Status (PS) 0-2 Note: for the cohort of patient that will be treated&#xD;
             with nivolumab and ipilimumab: PS 0-1&#xD;
&#xD;
          -  Availability of FFPE tumor tissue (a tumour block or 10 unstained slides), notably for&#xD;
             PD-L1 Immunohistochemistry (IHC) expression assessment. Archival material is allowed.&#xD;
             Patients will be eligible to participate regardless of the level of PD-L1 expression,&#xD;
             however tissue must be considered adequate (assessed by a local pathologist) for&#xD;
             characterization of PD-L1 status as per procedure manual;&#xD;
&#xD;
          -  Adequate hematological function:&#xD;
&#xD;
          -  white blood count ≥ 2 × 109/L;&#xD;
&#xD;
          -  haemoglobin &gt;9 g/dL;&#xD;
&#xD;
          -  platelet count &gt;100 × 109/L;&#xD;
&#xD;
          -  Adequate liver function:&#xD;
&#xD;
          -  Total bilirubin &lt;1.5 × ULN (except subjects with Gilbert Syndrome, who can have total&#xD;
             bilirubin &lt; 3.0 mg/dL);&#xD;
&#xD;
          -  ALT and/or AST &lt;2.5 × ULN (&lt; 4 x ULN in case of liver metastasis)&#xD;
&#xD;
          -  alkaline phosphatase &lt;5 × ULN;&#xD;
&#xD;
          -  Adequate renal function: calculated creatinine clearance ≥50 mL/min (according to&#xD;
             Cockroft- Gault, see below);&#xD;
&#xD;
          -  Female CrCl = ((140 - age in years) x weight in kg x 0.85)/ 72 x serum creatinine in&#xD;
             mg/dL;&#xD;
&#xD;
          -  Male CrCl = ((140 - age in years) x weight in kg x 1.00)/72 x serum creatinine in&#xD;
             mg/dL;&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within 72 hours prior to the first dose of study treatment.&#xD;
&#xD;
        Note: women of childbearing potential are defined as premenopausal females capable of&#xD;
        becoming pregnant (i.e. females who have had any evidence of menses in the past 12 months,&#xD;
        with the exception of those who had prior hysterectomy). However, women who have been&#xD;
        amenorrheic for 12 or more months are still considered to be of childbearing potential if&#xD;
        the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight,&#xD;
        ovarian suppression or other reasons.&#xD;
&#xD;
          -  Patients of childbearing / reproductive potential should use adequate birth control&#xD;
             measures, as defined by the investigator, during the study treatment period and for at&#xD;
             least 5 months for a woman and 7 months for a man after the last study treatment. A&#xD;
             highly effective method of birth control is defined as a method which results in a low&#xD;
             failure rate (i.e. less than 1% per year) when used consistently and correctly. Such&#xD;
             methods include:&#xD;
&#xD;
          -  Combined (estrogen and progestogen containing) hormonal contraception associated with&#xD;
             inhibition of ovulation (oral, intravaginal, transdermal)&#xD;
&#xD;
          -  Progestogen-only hormonal contraception associated with inhibition of ovulation (oral,&#xD;
             injectable, implantable)&#xD;
&#xD;
          -  Intrauterine device (IUD)&#xD;
&#xD;
          -  Intrauterine hormone-releasing system (IUS)&#xD;
&#xD;
          -  Bilateral tubal occlusion&#xD;
&#xD;
          -  Vasectomized partner&#xD;
&#xD;
          -  Sexual abstinence&#xD;
&#xD;
          -  Female patients who are breast feeding should discontinue nursing prior to the first&#xD;
             dose of study medication and must not be breast feeding during the trial treatment and&#xD;
             for a period of at least 5 months following the last administration of trial drug(s).&#xD;
&#xD;
          -  Before patient registration, written informed consent must be given according to&#xD;
             ICH/GCP, and national/local regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No evidence of active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Patients with previously treated brain metastases may participate provided&#xD;
             they are clinically stable (i.e. without evidence of progression by imaging for at&#xD;
             least four weeks prior to the enrollment and any neurologic symptoms have returned to&#xD;
             baseline), and have not received steroids (for a total equivalent dose of more than&#xD;
             10mg of prednisone per day) for at least 7 days prior to enrollment;&#xD;
&#xD;
          -  Prior treatment with anti-PD-1, anti-PD-L1/2, anti- CD137, CTLA-4 modulators;&#xD;
&#xD;
          -  Current participation to any other clinical research nor treatment with an&#xD;
             investigational agent or use of an investigational device within 4 weeks of the&#xD;
             enrollment;&#xD;
&#xD;
          -  Known history or current evidence of active Hepatitis B (e.g., HBsAg reactive) or C&#xD;
             (e.g., HCV RNA[qualitative] is detected) or Human Immunodeficiency Virus (HIV)&#xD;
             (HIV-1/2 antibodies);&#xD;
&#xD;
          -  Known contra-indications for CT with IV contrast&#xD;
&#xD;
          -  Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in&#xD;
             the last 15 days prior to enrollment&#xD;
&#xD;
          -  Corticosteroid use as premedication for IV contrast allergies/reactions is allowed;&#xD;
&#xD;
          -  Daily prednisone at doses up to 10 mg or equivalent doses of any othe corticosteroid&#xD;
             is allowed for example as replacement therapy&#xD;
&#xD;
          -  No history of interstitial lung disease (ILD) OR pneumonitis (other than COPD&#xD;
             exacerbation) that has required oral or IV steroids;&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in past 2 years (i.e.&#xD;
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).&#xD;
             Replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment and is allowed;&#xD;
&#xD;
          -  Live vaccines within 30 days prior to the first dose of study therapy and while&#xD;
             participating in study. Examples of live vaccines include, but are not limited to, the&#xD;
             following: measles, mumps, rubella, chicken pox, yellow fever, H1N1 flu, rabies, BCG,&#xD;
             and typhoid vaccine.&#xD;
&#xD;
          -  Autoimmune paraneoplastic syndrome requiring immunosuppressive or dedicated treatment.&#xD;
             A specific attention should be given in order to detect any minor myasthenia signs at&#xD;
             enrollment; acetylcholine receptor antibodies will be systematically tested when&#xD;
             symptoms are suggestive of a myasthenia;&#xD;
&#xD;
          -  History of any other hematologic or primary solid tumor malignancy, unless in&#xD;
             remission for at least 5 years. A pT1-2 prostatic cancer Gleason score &lt; 6,&#xD;
             superficial bladder cancer, non melanomatous skin cancer or carcinoma in situ of the&#xD;
             cervix is eligible;&#xD;
&#xD;
          -  Previous allogeneic tissue/solid organ transplant;&#xD;
&#xD;
          -  Active infection requiring therapy;&#xD;
&#xD;
          -  Surgery or chemotherapy related toxicity (toxicity resolved to grade 1, with the&#xD;
             exception of alopecia, fatigue, neuropathy and lack of appetite /nausea);&#xD;
&#xD;
          -  Severe comorbidities that in the opinion of the Investigator might hamper the&#xD;
             participation to the study and/or the treatment administration;&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient before registration in the trial;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Girard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Solange Peters</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Lausanne Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 1611</phone>
    <email>1525@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies Janssens, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Berghmans, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - La Tronche - Hôpital A. Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matteo Giaj Levra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Marseille - Hopital Nord (APHM)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Greillier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julien Mazieres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christelle Clement-Duchene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sjaak Burgers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monique Hochstenbag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joachim Aerts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institut d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susana Cedres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Ponce, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Solange Peters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandra Curioni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nazia Mohammed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Chelsea, London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sanjay Popat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Sutton, Surrey</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sanjay Popat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Wythenshawe</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yvonne Summers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thymoma</keyword>
  <keyword>Phase II</keyword>
  <keyword>nivolumab</keyword>
  <keyword>Thymic carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

